Clinical Trial Update: Ravulizumab Outcomes in Polish Patients With aHUS

View source ↗

Summary

A clinical trial evaluating ravulizumab outcomes in Polish patients with atypical hemolytic uremic syndrome is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Atypical Hemolytic Uremic Syndrome | Status: NOT_YET_RECRUITING